Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640495 | 0.86 | LMNA (0.40) | LMNAL3MBTL1ARCHRNA1CHRNB2 | |
| SCHEMBL7508721 | 0.73 | LMNA (0.55) | LMNAL3MBTL1CHRNA1CHRNB2CHRNA3 | |
| SCHEMBL27486788 | 0.71 | POLB (0.42) | CHRNB2CHRNA3CHRNA4KMT2AMEN1 | |
| SCHEMBL7503498 | 0.70 | CHRNA1 (0.51) | LMNAL3MBTL1ARCHRNA1CHRNB2 | |
| SCHEMBL17358144 | 0.68 | LMNA (0.40) | LMNAL3MBTL1ARCHRNA1CHRNB2 | |
| SCHEMBL7499950 | 0.68 | LMNA (0.68) | LMNAL3MBTL1CHRNA1CHRNB2CHRNA3 | |
| SCHEMBL29191568 | 0.68 | LMNA (0.57) | LMNAL3MBTL1CHRNA1CHRNB2CHRNA7 | |
| SCHEMBL5044718 | 0.67 | ALDH1A1 (0.68) | LMNAL3MBTL1CHRNA1CHRNB2CHRNA3 | |
| SCHEMBL7508741 | 0.67 | CHRNA1 (0.55) | LMNAL3MBTL1ARCHRNA1CHRNB2 | |
| SCHEMBL23431368 | 0.64 | GAA (0.65) | LMNAL3MBTL1CHRNA1CHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | SUNTORY LIMITED | 2002-03-07 | — | — | US | claimed |
| EP-1176141-A1 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR | SUNTORY LIMITED (JP) | 2002-01-30 | — | — | EP | claimed |
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | SUNTORY LIMITED | 2002-03-07 | — | — | US | disclosed |
| EP-1176141-A1 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR | SUNTORY LIMITED (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | CHRNA2, CHRNA7, CHRNB2 | LMNA 3137/4885L3MBTL1 2586/4885AR 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.